60 Degrees Pharmaceuticals Reports Clinical Improvement and Negative PCR Results in Completed Babesiosis Study
The company said all patients who completed its expanded-access babesiosis study showed clinical improvement and had negative PCR results.
Story updates
12:13:19 PM UTC
SquawkNews
60 Degrees Pharmaceuticals reported clinical improvement and negative conventional PCR results in all five patients who completed its expanded access study for relapsing babesiosis.Key Highlights:Original SEC Filing: 60 DEGREES PHARMACEUTICALS, INC. [ SXTP ] - 8-K - Oct. 27, 2026This is an AI-power…
12:14:25 PM UTC
SquawkNews
WASHINGTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced clinical and molecular results from the first five patients to…